Jaw Problem Tied to Bisphosphonates
BOSTON—IV bisphosphonates may increase the risk of osteonecrosis of the jaw (ONJ), according to new findings.
Diagnosis & Disease Information
Incontinence Not Always Progressive
Urinary incontinence in women is not necessarily progressive, but rather it is a dynamic process, Austrian researchers have concluded.
HbA1c Influences GFR Estimates
Glucose control influences glomerular filtration rate (GFR) and its estimations in patients with type 1 or 2 diabetes, a French study found.
Patient-Friendly Software for Diabetic Monitoring Cleared
DexCom, Inc., of San Diego has received approval for its DM Consumer Data Manager, a software program that allows diabetic patients to download and view up to 30 days of historical glucose data from their DexCom STS Continuous Glucose Monitoring Systems.
Further Data on Diabetic Retinopathy Drug Requested
Eli Lilly and Company has received an approvable letter from the FDA requesting additional supporting data for its new drug application for ruboxistaurin mesylate (proposed trade name: Arxxant), Lilly’s investigational oral therapy for diabetic retinopathy.
BPH Treatment Device Returns to Market
Celsion Corporation of Columbia, Md., has announced it will resume shipments of its Prolieve Thermodilatation system for benign prostatic hyperplasia after clearance from the FDA’s Center for Devices and Radiological Health.
Prostate Cancer Vaccine Evidence Submitted
Dendreon Corporation of Seattle has presented to the FDA the clinical and non-clinical sections of its rolling submission of a Biologics License Application (BLA) for Provenge (sipuleucel-T).
New Autoinjector for CKD-Associated Anemia
Amgen is launching its recently approved Aranesp (darbepoetin alfa) prefilled SureClick autoinjector for patients with anemia associated with CKD and chemotherapy-induced anemia.
HoLEP, TURP Equivalent at Two Years
Holmium laser enucleation of the prostate (HoLEP) provides two-year outcomes equivalent to that of open prostatectomy in treating men with large prostates, according to two studies.
Expectant Management A Viable Option
ATLANTA—Delayed intervention for treating small renal masses may be appropriate for selected patients, especially those with competing comorbidities, a study found. This conservative approach has little adverse effect on pathological and clinical outcomes, researchers note.
- Loading...
Loading...
Loading... 
Loading...